Growth in this market is mainly driven by the increasing prevalence of diseases requiring surgical treatment, especially minimally invasive surgery (MIS). However, the high cost of ligation devices is a major restraint for this market, particularly in emerging countries.
“Increasing use of ligation devices in gastrointestinal & abdominal surgeries to drive market growth during the forecast period”
Based on applications, the ligation devices market is segmented into gastrointestinal & abdominal surgeries, gynecological surgeries, cardiovascular surgeries, urological surgeries, and other applications such as wound, ENT, and cosmetic applications. The cardiovascular surgeries segment is anticipated to drive growth in the market at a CAGR of 6.9% over the forecast period. This growth can be attributed to the increase in the incidence of cardiovascular diseases. Additionally, with technological advancements in cardiovascular robotic surgery, the demand for ligation devices is anticipated to increase.
“Asia Pacific to grow at the highest rate during the forecast period (2018–2023)”
The ligation devices market is geographically segmented into North America, Europe, Asia Pacific, and the Rest of the World (RoW). While North America dominated the market in 2018, Asia Pacific is expected to register the highest CAGR in the market during the forecast period. Growth in the APAC region is largely driven by the large patient population and increasing infrastructural development in the region.
Download PDF - https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=22007372
Key Market Players
Some of the prominent players in the ligation devices market are are Ethicon (Johnson and Johnson) (US), Teleflex Incorporated (US), Olympus (Japan), Applied Medical (US), ConMed (US), Cooper Surgical (US), Genicon (US), Grena Think Medical (UK), B.Braun (Germany), and Medtronic (Ireland).
Johnson & Johnson (Ethicon) is the largest player in the ligation devices market. The company focuses on the development of devices, consumables, accessories, and software required to perform minimally invasive surgeries and open surgeries. The company also invests a significant amount on research and development activities. In 2018, it spent ~7% of its revenue on R&D activities.
Medtronic (Covidien) is a major player in the ligation devices market. The company has a global distribution network and a good brand reputation among end users. The company’s strong presence and wide distribution channels across the globe have helped it to maintain its leading position in the ligation devices market.
Know more about Ligation Devices Market - https://www.marketsandmarkets.com/PressReleases/ligation-device.asp
OPKO Health (Nasdaq: OPK) and Pfizer (NYSE: PFE) Announce Positive Phase 3 Top-Line Results for Somatrogon, an Investigational Long-Acting Human Growth Hormone to Treat Children with Growth Hormone Deficiency
**Disclaimer: Crown Equity Holdings Inc. has received $5,000.00 (five thousand dollars) in cash from Nass Valley Gateway Ltd. (CSE:NVG) (FSE:3NVN) for 30 days of advertisement services